

Unlike larger panels, the FOLLOW IT panel is focused on gene mutations that you can tackle through current Health Canada approved therapies.

Indication	Biomarker	Health Canada approved therapy
Non-Small Cell Lung Cancer	EGFR exon 19 deletions and EGFR exon 21 L858R alterations	Giotrif® (afatinib), Iressa® (gefitinib), or Tarceva® (erlotinib) Vizimpro (dacomitinib) - specific to exon 19 del or exon 21 L858R variants
	EGFR exon 20 resistance T790M alterations and first line in common L858R and exon 19 del	Tagrisso® (osimertinib)
	BRAF V600E	Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)
	ALK resistance mutations	Alunbrig® (brigatinib) Lorbrena® (lorlatinib) - (progressed or resistant to crizotinib & at least one other ALK inhibitor NOC/c)
Melanoma	BRAF V600E	Tafinlar® (dabrafenib) or Zelboraf® (vemurafenib)
	BRAF V600E or V600K	Mekinist® (trametinib) in combination with Tafinlar® (dabrafenib) or Cotellic® (cobimetinib) in combination with Zelboraf® (vemurafenib) Keytruda® (pembrolizumab) when progression occurs on ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor
Colorectal Cancer	RAS negative	Erbix® (cetuximab)
	KRAS and NRAS wild-type	Vectibix® (panitumumab)
GIST	KIT, PDGFRA	Gleevec® (imatinib) Sutent® (sunitinib) Stivarga® (regorafenib)
Basal Cell	PTCH1	Vismodegib® (erivedge)
Breast Cancer	PIK3CA	Piqray® (alpelisib)